NYOH patients who need documentation to confirm eligibility to receive the COVID-19 vaccine, visit our COVID-19 resource page to learn how.
Learn More

Clinical Trials & Research

GU-102 Ph I/II Nivo + axitinib RCC

Phase I/II Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma

Disease Types: Renal,&nbs

Available at: {clinical_trial_location backspace="7"}GU-102 Ph I/II Nivo + axitinib RCC, {/clinical_trial_location}

Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}

{clinical_trial_description}